# 606070

AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21


Alternative titles; symbols

MYOPATHY, DISTAL, 2, FORMERLY; MPD2, FORMERLY
VOCAL CORD AND PHARYNGEAL DYSFUNCTION WITH DISTAL MYOPATHY, FORMERLY; VCPDM, FORMERLY


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
5q31.2 Amyotrophic lateral sclerosis 21 606070 AD 3 MATR3 164015
Clinical Synopsis
   
Phenotypic Series

INHERITANCE
- Autosomal dominant
HEAD & NECK
Face
- Bulbar weakness
Eyes
- Extraocular muscle weakness (in some patients)
RESPIRATORY
- Respiratory insufficiency due to muscle weakness
Nasopharynx
- Pharyngeal muscle weakness
Larynx
- Vocal cord weakness
- Bowing of the vocal cords
- Incomplete closure of the glottis
- Aspiration
ABDOMEN
Gastrointestinal
- Dysphagia
MUSCLE, SOFT TISSUES
- Distal muscle weakness
- Onset of weakness in hands and feet
- Shoulder weakness
- Neuropathic or myopathic changes seen on EMG
- Noninflammatory myopathy with rimmed vacuoles and atrophic fibers seen on muscle biopsy
NEUROLOGIC
Central Nervous System
- Amyotrophic lateral sclerosis
- Upper motor neuron signs
- Lower motor neuron signs
- Bulbar signs
- Dysarthria
- Hyperreflexia
- Dementia (1 family)
Peripheral Nervous System
- Nerve conduction velocity (NCV) slowing (1 family)
- Distal sensory impairment (1 family)
VOICE
- Hypophonic, breathy voice
- Wet, gurgling, hoarse voice
LABORATORY ABNORMALITIES
- Increased serum creatine kinase
MISCELLANEOUS
- Adult onset
- Can be slowly or rapidly progressive
- Variable severity
MOLECULAR BASIS
- Caused by mutation in the matrin-3 gene (MATR3, 164017.0001)
Amyotrophic lateral sclerosis - PS105400 - 32 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia AD 3 616208 TUBA4A 191110
3p11.2 Amyotrophic lateral sclerosis 17 AD 3 614696 CHMP2B 609512
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 3 613954 VCP 601023
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 3 613435 OPTN 602432
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPB 605704
21q22.11 Amyotrophic lateral sclerosis 1 AR, AD 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 ?{Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia 205200 ALSDC 205200

TEXT

A number sign (#) is used with this entry because amyotrophic lateral sclerosis-21 (ALS21) is caused by heterozygous mutation in the matrin-3 gene (MATR3; 164015) on chromosome 5q31.


Description

Amyotrophic lateral sclerosis-21 is an autosomal dominant neurodegenerative disorder affecting upper and lower motor neurons, resulting in muscle weakness and respiratory failure. Some patients may develop myopathic features or dementia (summary by Johnson et al., 2014).

For a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Feit et al. (1998) described a large American family segregating an autosomal dominant distal myopathy, with multiple affected individuals in whom vocal cord and pharyngeal weakness may accompany the distal myopathy, without involvement of the ocular muscles. From a histopathologic standpoint, the lesion observed in these individuals was a noninflammatory myopathy with rimmed vacuoles probably fitting into the spectrum of the inclusion-bodied myopathies. Overall, the myopathy was mild or moderate. They stated that this 'form of distal myopathy has not been previously recognized and is distinct from other myopathies with pharyngeal or vocal weakness.' They referred to the clinical disorder as VCPDM (vocal cord and pharyngeal dysfunction with distal myopathy). Senderek et al. (2009) expanded the family described by Feit et al. (1998) with 2 additional sibs from an additional branch of the family. They also described a multigenerational Bulgarian family with a typical VCPDM phenotype. Upon reexamination of the family originally reported by Feit et al. (1998), Johnson et al. (2014) found that affected individuals developed progressive respiratory failure resulting in death about 15 years after symptom onset. Four of 6 patients examined showed hyperreflexia of the lower limbs, indicative of upper motor neuron involvement. One patient also had hyperreflexia of the upper limbs, tongue fasciculations, and a brisk jaw jerk. All patients had a 'split-hand' pattern of weakness, suggestive of a lesion in the anterior horn of the spinal cord. These clinical findings led Johnson et al. (2014) to reclassify the disorder in this family as a form of slowly progressive amyotrophic lateral sclerosis rather than a myopathy. Many of the patients in this family also had significant distal sensory impairment of the lower limbs.

Johnson et al. (2014) reported a large family of European origin segregating ALS and dementia in an autosomal dominant pattern of inheritance. Clinical details of 5 patients were provided, although family history suggested that other deceased family members had been affected. The age at onset ranged from the early fifties to the seventies and was characterized by distal muscle weakness and cramping of the upper or lower limbs, and bulbar signs, such as dysarthria and dysphagia. All patients developed progressive upper and lower motor neuron signs affecting all 4 limbs, and at least 3 patients died of respiratory failure. Most patients also had cognitive impairment or dementia. Two affected individuals from an unrelated Sardinian family had onset of distal muscle weakness at ages 60 and 62 years, respectively. Imaging of 1 patient showed bilateral corticospinal tract damage. The other patient developed upper motor neuron signs and died of respiratory failure 33 months after onset. In a third family, an Indian man developed upper limb weakness at age 59 years. The symptoms spread to the lower limbs and bulbar muscles over the following 3 years, and he eventually became confined to a wheelchair and required ventilatory support, a gastrostomy tube, and an eye-tracking system for communication.

Muller et al. (2014) reported 16 patients from 6 unrelated German families with the S85C MATR3 mutation (164015.0001); haplotype analysis indicated a founder effect. The mean age at onset was 42.2 years (range, 30-55 years). Twelve patients presented with stumbling when walking uphill or climbing stairs due to weakness of the ankle dorsiflexors; 4 had difficulties rising from a squat due to muscle weakness of the proximal lower limbs; 2 had myalgia; and 2 had impaired hand function. Muscle weakness, which predominantly affected the distal lower limbs and the hands and fingers, was sometimes associated with muscle atrophy. Proximal muscle, neck muscle, and axial muscle weakness occurred in some patients, but was not common and tended to occur later in the disease course. Spasticity, hyperreflexia, and extensor plantar responses were not found, and tongue atrophy or fasciculations were not observed. Six patients had a nasal voice and 1 had a hoarse voice, but there was no evidence of vocal cord palsy. Six patients reported dysphagia of solid foods. Respiratory vital capacity was slightly decreased in 9 patients, and 3 needed assisted ventilation or oxygen therapy. Ten patients had increased serum creatine kinase, and EMG showed reduced amplitude and shortened duration of the motor unit potential. Muscle MRI showed fatty replacement of the thighs and lower legs, and muscle biopsies showed variable myopathic changes, including variation in fiber size, internal nuclei, and fatty replacement. Immunostaining showed MATR3 reactivity within muscle nuclei, but electron microscopy showed abnormal invaginations of the nucleus, perinuclear absence of sarcomeres, and presence of vacuoles. Muller et al. (2014) emphasized the lack of symptoms of motor neuron disease in these patients and suggested that the phenotype was more consistent with a distal myopathy than with ALS.


Inheritance

The transmission pattern in the families with ALS21 reported by Johnson et al. (2014) was consistent with autosomal dominant inheritance.


Mapping

By use of combined genome screening and DNA pooling adapted to fluorescent markers, Feit et al. (1998) mapped the gene for the disorder, which they designated MPD2, to 5q, within a 12-cM interval between markers D5S458 and D5S1972 in this large pedigree (maximum lod score = 12.94 at a recombination fraction of 0.0 for D5S393).

In the family originally described by Feit et al. (1998), Senderek et al. (2009) reduced the candidate interval to a 5.37-Mb region on chromosome 5q31, between short tandem repeat (STR) markers sara2AC and AC008667C.


Molecular Genetics

In the family described by Feit et al. (1998) and in an unrelated Bulgarian family with vocal cord and pharyngeal weakness with distal myopathy, Senderek et al. (2009) identified the same heterozygous missense mutation in the MATR3 gene (S85C; 164015.0001), which encodes a component of the nuclear matrix. Johnson et al. (2014) reclassified the disorder in the family reported by Feit et al. (1998) as ALS.

In affected members of a family of European ancestry with ALS21, Johnson et al. (2014) identified a heterozygous missense mutation in the MATR3 gene (F115C; 164015.0002). The mutation was found by exome sequencing. Most affected individuals in this family also had cognitive impairment or dementia. Exome sequence data from 108 additional familial ALS cases identified 1 heterozygous MATR3 missense mutation (T622A; 164015.0003) in an affected family. In addition, custom resequencing of genes linked to neurodegeneration in 96 British ALS cases identified a heterozygous mutation (P154S; 164015.0004) in a patient with sporadic disease. Immunohistochemical analysis of spinal cord section from a patient with the F115C mutation showed intense MATR3 immunoreactivity in the nucleus of all motor neurons and diffuse cytoplasmic staining in many neurons. Cytoplasmic inclusions were not present. Similar studies of spinal cord section from a patient with FTDALS (105550) due to the C9ORF72 repeat expansion (614260.0001) showed rare MATR3-positive cytoplasmic inclusions. MATR3 was also observed in the nuclei of remaining motor neurons and occasionally in the cytoplasm of spinal cord sections from non-MATR3 ALS. The findings suggested a role for aberrant RNA processing in motor neuron degeneration.


Nomenclature

Feit et al. (1998) adopted the gene symbol MPD2 following the precedent of Laing et al. (1995), who had designated a form of distal myopathy that maps to 14q as MPD1 (160500). However, the disorder in the family reported by Feit et al. (1998) was later reclassified as amyotrophic lateral sclerosis by Johnson et al. (2014).


See Also:

REFERENCES

  1. Feit, H., Silbergleit, A., Schneider, L. B., Gutierrez, J. A., Fitoussi, R.-P., Reyes, C., Rouleau, G. A., Brais, B., Jackson, C. E., Beckmann, J. S., Seboun, E. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am. J. Hum. Genet. 63: 1732-1742, 1998. [PubMed: 9837826, related citations] [Full Text]

  2. Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E., Pliner, H. A., Abramzon, Y., Marangi, G., Winborn, B. J., Gibbs, J.R., Nalls, M. A., and 30 others. Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neurosci. 17: 664-666, 2014. [PubMed: 24686783, images, related citations] [Full Text]

  3. Laing, N. G., Laing, B. A., Meredith, C., Wilton, S. D., Robbins, P., Honeyman, K., Dorosz, S., Kozman, H., Mastaglia, F. L., Kakulas, B. A. Autosomal dominant distal myopathy: linkage to chromosome 14. Am. J. Hum. Genet. 56: 422-427, 1995. [PubMed: 7847377, related citations]

  4. Muller, T. J., Kraya, T., Stoltenburg-Didinger, G., Hanisch, F., Kornhuber, M., Stoevesandt, D., Senderek, J., Weis, J., Baum, P., Deschauer, M., Zierz, S. Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann. Neurol. 76: 669-680, 2014. [PubMed: 25154462, related citations] [Full Text]

  5. Senderek, J., Garvey, S. M., Krieger, M., Guergueltcheva, V., Urtizberea, A., Roos, A., Elbracht, M., Stendel, C., Tournev, I., Mihailova, V., Feit, H., Tramonte, J., and 11 others. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum. Genet. 84: 511-518, 2009. [PubMed: 19344878, images, related citations] [Full Text]

  6. Young, I. D., Harper, P. S. Hereditary distal spinal muscular atrophy with vocal cord paralysis. J. Neurol. Neurosurg. Psychiat. 43: 413-418, 1980. [PubMed: 7420092, related citations] [Full Text]


Cassandra L. Kniffin - updated : 4/1/2015
Cassandra L. Kniffin - updated : 4/14/2014
Creation Date:
Victor A. McKusick : 6/27/2001
carol : 10/05/2016
carol : 04/02/2015
mcolton : 4/1/2015
ckniffin : 4/1/2015
mcolton : 8/12/2014
carol : 4/15/2014
mcolton : 4/14/2014
ckniffin : 4/14/2014
wwang : 7/1/2011
alopez : 10/20/2009
mgross : 3/15/2005
alopez : 3/18/2004
ckniffin : 5/2/2003
ckniffin : 4/29/2003
ckniffin : 4/14/2003
ckniffin : 4/14/2003
carol : 2/21/2003
carol : 6/27/2001

# 606070

AMYOTROPHIC LATERAL SCLEROSIS 21; ALS21


Alternative titles; symbols

MYOPATHY, DISTAL, 2, FORMERLY; MPD2, FORMERLY
VOCAL CORD AND PHARYNGEAL DYSFUNCTION WITH DISTAL MYOPATHY, FORMERLY; VCPDM, FORMERLY


ORPHA: 803, 600;   DO: 0060212;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
5q31.2 Amyotrophic lateral sclerosis 21 606070 Autosomal dominant 3 MATR3 164015

TEXT

A number sign (#) is used with this entry because amyotrophic lateral sclerosis-21 (ALS21) is caused by heterozygous mutation in the matrin-3 gene (MATR3; 164015) on chromosome 5q31.


Description

Amyotrophic lateral sclerosis-21 is an autosomal dominant neurodegenerative disorder affecting upper and lower motor neurons, resulting in muscle weakness and respiratory failure. Some patients may develop myopathic features or dementia (summary by Johnson et al., 2014).

For a discussion of genetic heterogeneity of amyotrophic lateral sclerosis, see ALS1 (105400).


Clinical Features

Feit et al. (1998) described a large American family segregating an autosomal dominant distal myopathy, with multiple affected individuals in whom vocal cord and pharyngeal weakness may accompany the distal myopathy, without involvement of the ocular muscles. From a histopathologic standpoint, the lesion observed in these individuals was a noninflammatory myopathy with rimmed vacuoles probably fitting into the spectrum of the inclusion-bodied myopathies. Overall, the myopathy was mild or moderate. They stated that this 'form of distal myopathy has not been previously recognized and is distinct from other myopathies with pharyngeal or vocal weakness.' They referred to the clinical disorder as VCPDM (vocal cord and pharyngeal dysfunction with distal myopathy). Senderek et al. (2009) expanded the family described by Feit et al. (1998) with 2 additional sibs from an additional branch of the family. They also described a multigenerational Bulgarian family with a typical VCPDM phenotype. Upon reexamination of the family originally reported by Feit et al. (1998), Johnson et al. (2014) found that affected individuals developed progressive respiratory failure resulting in death about 15 years after symptom onset. Four of 6 patients examined showed hyperreflexia of the lower limbs, indicative of upper motor neuron involvement. One patient also had hyperreflexia of the upper limbs, tongue fasciculations, and a brisk jaw jerk. All patients had a 'split-hand' pattern of weakness, suggestive of a lesion in the anterior horn of the spinal cord. These clinical findings led Johnson et al. (2014) to reclassify the disorder in this family as a form of slowly progressive amyotrophic lateral sclerosis rather than a myopathy. Many of the patients in this family also had significant distal sensory impairment of the lower limbs.

Johnson et al. (2014) reported a large family of European origin segregating ALS and dementia in an autosomal dominant pattern of inheritance. Clinical details of 5 patients were provided, although family history suggested that other deceased family members had been affected. The age at onset ranged from the early fifties to the seventies and was characterized by distal muscle weakness and cramping of the upper or lower limbs, and bulbar signs, such as dysarthria and dysphagia. All patients developed progressive upper and lower motor neuron signs affecting all 4 limbs, and at least 3 patients died of respiratory failure. Most patients also had cognitive impairment or dementia. Two affected individuals from an unrelated Sardinian family had onset of distal muscle weakness at ages 60 and 62 years, respectively. Imaging of 1 patient showed bilateral corticospinal tract damage. The other patient developed upper motor neuron signs and died of respiratory failure 33 months after onset. In a third family, an Indian man developed upper limb weakness at age 59 years. The symptoms spread to the lower limbs and bulbar muscles over the following 3 years, and he eventually became confined to a wheelchair and required ventilatory support, a gastrostomy tube, and an eye-tracking system for communication.

Muller et al. (2014) reported 16 patients from 6 unrelated German families with the S85C MATR3 mutation (164015.0001); haplotype analysis indicated a founder effect. The mean age at onset was 42.2 years (range, 30-55 years). Twelve patients presented with stumbling when walking uphill or climbing stairs due to weakness of the ankle dorsiflexors; 4 had difficulties rising from a squat due to muscle weakness of the proximal lower limbs; 2 had myalgia; and 2 had impaired hand function. Muscle weakness, which predominantly affected the distal lower limbs and the hands and fingers, was sometimes associated with muscle atrophy. Proximal muscle, neck muscle, and axial muscle weakness occurred in some patients, but was not common and tended to occur later in the disease course. Spasticity, hyperreflexia, and extensor plantar responses were not found, and tongue atrophy or fasciculations were not observed. Six patients had a nasal voice and 1 had a hoarse voice, but there was no evidence of vocal cord palsy. Six patients reported dysphagia of solid foods. Respiratory vital capacity was slightly decreased in 9 patients, and 3 needed assisted ventilation or oxygen therapy. Ten patients had increased serum creatine kinase, and EMG showed reduced amplitude and shortened duration of the motor unit potential. Muscle MRI showed fatty replacement of the thighs and lower legs, and muscle biopsies showed variable myopathic changes, including variation in fiber size, internal nuclei, and fatty replacement. Immunostaining showed MATR3 reactivity within muscle nuclei, but electron microscopy showed abnormal invaginations of the nucleus, perinuclear absence of sarcomeres, and presence of vacuoles. Muller et al. (2014) emphasized the lack of symptoms of motor neuron disease in these patients and suggested that the phenotype was more consistent with a distal myopathy than with ALS.


Inheritance

The transmission pattern in the families with ALS21 reported by Johnson et al. (2014) was consistent with autosomal dominant inheritance.


Mapping

By use of combined genome screening and DNA pooling adapted to fluorescent markers, Feit et al. (1998) mapped the gene for the disorder, which they designated MPD2, to 5q, within a 12-cM interval between markers D5S458 and D5S1972 in this large pedigree (maximum lod score = 12.94 at a recombination fraction of 0.0 for D5S393).

In the family originally described by Feit et al. (1998), Senderek et al. (2009) reduced the candidate interval to a 5.37-Mb region on chromosome 5q31, between short tandem repeat (STR) markers sara2AC and AC008667C.


Molecular Genetics

In the family described by Feit et al. (1998) and in an unrelated Bulgarian family with vocal cord and pharyngeal weakness with distal myopathy, Senderek et al. (2009) identified the same heterozygous missense mutation in the MATR3 gene (S85C; 164015.0001), which encodes a component of the nuclear matrix. Johnson et al. (2014) reclassified the disorder in the family reported by Feit et al. (1998) as ALS.

In affected members of a family of European ancestry with ALS21, Johnson et al. (2014) identified a heterozygous missense mutation in the MATR3 gene (F115C; 164015.0002). The mutation was found by exome sequencing. Most affected individuals in this family also had cognitive impairment or dementia. Exome sequence data from 108 additional familial ALS cases identified 1 heterozygous MATR3 missense mutation (T622A; 164015.0003) in an affected family. In addition, custom resequencing of genes linked to neurodegeneration in 96 British ALS cases identified a heterozygous mutation (P154S; 164015.0004) in a patient with sporadic disease. Immunohistochemical analysis of spinal cord section from a patient with the F115C mutation showed intense MATR3 immunoreactivity in the nucleus of all motor neurons and diffuse cytoplasmic staining in many neurons. Cytoplasmic inclusions were not present. Similar studies of spinal cord section from a patient with FTDALS (105550) due to the C9ORF72 repeat expansion (614260.0001) showed rare MATR3-positive cytoplasmic inclusions. MATR3 was also observed in the nuclei of remaining motor neurons and occasionally in the cytoplasm of spinal cord sections from non-MATR3 ALS. The findings suggested a role for aberrant RNA processing in motor neuron degeneration.


Nomenclature

Feit et al. (1998) adopted the gene symbol MPD2 following the precedent of Laing et al. (1995), who had designated a form of distal myopathy that maps to 14q as MPD1 (160500). However, the disorder in the family reported by Feit et al. (1998) was later reclassified as amyotrophic lateral sclerosis by Johnson et al. (2014).


See Also:

<a href="#Young1980" class="entry-reference" title="Young, I. D., Harper, P. S. Hereditary distal spinal muscular atrophy with vocal cord paralysis. J. Neurol. Neurosurg. Psychiat. 43: 413-418, 1980.">Young and Harper (1980)</a>

REFERENCES

  1. Feit, H., Silbergleit, A., Schneider, L. B., Gutierrez, J. A., Fitoussi, R.-P., Reyes, C., Rouleau, G. A., Brais, B., Jackson, C. E., Beckmann, J. S., Seboun, E. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am. J. Hum. Genet. 63: 1732-1742, 1998. [PubMed: 9837826] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(07)61618-8]

  2. Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E., Pliner, H. A., Abramzon, Y., Marangi, G., Winborn, B. J., Gibbs, J.R., Nalls, M. A., and 30 others. Mutations in the matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neurosci. 17: 664-666, 2014. [PubMed: 24686783] [Full Text: https://dx.doi.org/10.1038/nn.3688]

  3. Laing, N. G., Laing, B. A., Meredith, C., Wilton, S. D., Robbins, P., Honeyman, K., Dorosz, S., Kozman, H., Mastaglia, F. L., Kakulas, B. A. Autosomal dominant distal myopathy: linkage to chromosome 14. Am. J. Hum. Genet. 56: 422-427, 1995. [PubMed: 7847377]

  4. Muller, T. J., Kraya, T., Stoltenburg-Didinger, G., Hanisch, F., Kornhuber, M., Stoevesandt, D., Senderek, J., Weis, J., Baum, P., Deschauer, M., Zierz, S. Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann. Neurol. 76: 669-680, 2014. [PubMed: 25154462] [Full Text: https://dx.doi.org/10.1002/ana.24255]

  5. Senderek, J., Garvey, S. M., Krieger, M., Guergueltcheva, V., Urtizberea, A., Roos, A., Elbracht, M., Stendel, C., Tournev, I., Mihailova, V., Feit, H., Tramonte, J., and 11 others. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am. J. Hum. Genet. 84: 511-518, 2009. [PubMed: 19344878] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0002-9297(09)00103-7]

  6. Young, I. D., Harper, P. S. Hereditary distal spinal muscular atrophy with vocal cord paralysis. J. Neurol. Neurosurg. Psychiat. 43: 413-418, 1980. [PubMed: 7420092] [Full Text: http://jnnp.bmj.com/cgi/pmidlookup?view=long&pmid=7420092]


Contributors:
Cassandra L. Kniffin - updated : 4/1/2015
Cassandra L. Kniffin - updated : 4/14/2014
Creation Date:
Victor A. McKusick : 6/27/2001
Edit History:
carol : 10/05/2016
carol : 04/02/2015
mcolton : 4/1/2015
ckniffin : 4/1/2015
mcolton : 8/12/2014
carol : 4/15/2014
mcolton : 4/14/2014
ckniffin : 4/14/2014
wwang : 7/1/2011
alopez : 10/20/2009
mgross : 3/15/2005
alopez : 3/18/2004
ckniffin : 5/2/2003
ckniffin : 4/29/2003
ckniffin : 4/14/2003
ckniffin : 4/14/2003
carol : 2/21/2003
carol : 6/27/2001